<DOC>
	<DOCNO>NCT00938587</DOCNO>
	<brief_summary>This study investigate safety efficacy investigational drug , PF-04171327 sign symptom rheumatoid arthritis patient require glucocorticoid background methotrexate . This study also look response chemical biological marker rheumatoid arthritis patient . Lastly , study measure PK ( amount drug blood ) methotrexate patient may take PF-04171327 .</brief_summary>
	<brief_title>A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Patients ≥ 18 year age , diagnose rheumatoid arthritis minimum duration 3 month On stable dose methotrexate least 6 week prior screen Patient must minimum disease activity level ≥ 6 tender/painful joint , ≥ 6 swollen joint CRP ≥ 0.7 mg/dL Not currently receive steroid medication Pregnant nursing woman Patients active infection , TB , HIV and/or Hepatitis B C Patients history intolerance significant adverse effect use glucocorticoid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Rheumatoid Arthritis Glucocorticoids Prednisone</keyword>
</DOC>